The monoclonal antibodies trastuzumab and avelumab, which target HER2 or PD-L1 respectively, are currently FDA approved and have been shown to induce durable tumor remissions in various advanced solid cancers (17, 18). This evidence concerns the gene CD274 and neoplasm.